Immutep (IMM) Corporate presentation summary

Strategic positioning and pipeline overview

• Leading developer of LAG-3 immunotherapies with a diversified pipeline in oncology and autoimmune diseases, including first-in-class assets efti and IMP761.

• Four clinical-stage assets target high unmet needs via MHC Class II and LAG-3 pathways.

• Multiple collaborations and licensing agreements with major pharma, including Dr. Reddy's, MSD, and academic institutions.

• Strong IP portfolio with 12+ years of exclusivity and cash runway into H1 2028.

Oncology clinical development

• Efti demonstrated broad immune activation and improved survival in earlier trials when combined with standard-of-care therapies.

• TACTI-002 and INSIGHT-003 trials showed strong efficacy for efti + KEYTRUDA, especially in NSCLC across all PD-L1 levels.

• TACTI-004 Phase III trial in 1L NSCLC was discontinued after a futility analysis; typical immune activation was not observed in this study.

• Efti is advancing in head and neck cancer (HNSCC) with FDA Fast Track for CPS <1 population and promising Phase II results.

• In soft tissue sarcoma, efti + pembrolizumab + radiotherapy met primary endpoint with significant immune activation and tumour fibrosis, supporting further development.

Autoimmune disease program

• IMP761 is a first-in-class LAG-3 agonist antibody designed to silence autoreactive T cells, targeting the root cause of autoimmune diseases.

• LAG-3 pathway offers a unique, non-redundant mechanism with potential for favorable safety and chronic dosing.

• Phase I trial of IMP761 in healthy volunteers met primary endpoint for safety and showed significant pharmacodynamic activity at 7 mg/kg, supporting further clinical investigation.

• IMP761 targets large markets including rheumatoid arthritis, type 1 diabetes, and multiple sclerosis.